In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla_NDM, bla_KPC, and ESBL-Producing Enterobacteriales Uropathogens.

ABSTRACT: Antibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infections caused by drug-resistant pathogens. This study was designed to screen Enterobacteriales isolates from UTI patients and to assess their antimicrobial resistance pattern, particularly against the mentioned (new) antibiotics. Phenotypic screening of extended-spectrum β-lactamase (ESBL) and carbapenem resistance was followed by inhibitor-based assays to detect K. pneumoniae carbapenemase (KPC), metallo-β-lactamase (MBL), and class D oxacillinases (OXA). Among 289 Enterobacteriales,

SUBMITTER: Razaq L 

PROVIDER: S-EPMC10604030 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature